Compare VSME & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VSME | SNGX |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 5.6M |
| IPO Year | 2022 | 2006 |
| Metric | VSME | SNGX |
|---|---|---|
| Price | $1.17 | $0.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 49.5K | ★ 174.7K |
| Earning Date | 10-31-2025 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $119,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $0.28 |
| 52 Week High | $5.38 | $3.36 |
| Indicator | VSME | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 41.76 | 47.68 |
| Support Level | $1.05 | $0.37 |
| Resistance Level | $1.19 | $0.41 |
| Average True Range (ATR) | 0.11 | 0.01 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 13.63 | 12.45 |
VS Media Holdings Ltd manages a network of digital Creators who create and publish content to social media platforms such as YouTube, Facebook, Instagram, and TikTok. Its Creators include influencers, KOLs-Key Opinion Leaders, bloggers, and other content creators who cultivate fan bases on social media platforms. The company's business provides value to two business stakeholders: marketing services and social commerce. The firm generates almost all of its revenue from marketing services, which reflects the company's business of marketing services to clients and social media platforms. The social commerce segment reflects the company's business of social commerce with customers. Geographically, the firm generates revenue from the HK SAR and Taiwan.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).